Publisher: Adis International
ISSN: 1173-5503
Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.515, 2006-01, pp. : 11-11
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Early initiation of irbesartan provides maximum cost benefits
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 460, 2004-01 ,pp. :
Use of Routine Healthcare Data in Safe and Cost-Effective Drug Use
By Currie C.J.
Drug Safety, Vol. 22, Iss. 2, 2000-02 ,pp. :
Natalizumab shows clinical, cost and QOL benefits
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 514, 2006-01 ,pp. :
By Stevenson Matt D. Scope Alison Sutcliffe Paul A.
Value in Health, Vol. 13, Iss. 5, 2010-08 ,pp. :